Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma

作     者：Yuekun Wang Shenglan Li Yichen Peng Wenbin Ma Yu Wang Wenbin Li 

作者机构：Department of NeurosurgeryPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of Neuro-oncologyCancer CenterBeijing Tiantan HospitalCapital Medical UniversityBeijingChina 

出 版 物：《Cancer Innovation》 (肿瘤创新（英文）)

年 卷 期：2023年第2卷第2期

页      面：114-130页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Clinical Major Specialty Projects of Beijing National High Level Hospital Clinical Research Funding,Grant/Award Number:2022-PUMCH-A-019 

主　　题：glioblastoma immunotherapy phase III clinical trial target therapy 

摘      要：Glioblastoma(GBM)is the most common primary central nervous system tumor,whose prognosis remains poor under the sequential standard of care,such as neurosurgery followed by concurrent temozolomide radiochemotherapy and adjuvant temozolomide chemotherapy in the presence or absence of tumor treating ***,the advent of molecular targeted therapy and immunotherapy has opened a new era of tumor management.A diverse range of targeted drugs have been tested in patients with GBM in phase III clinical ***,these drugs are ineffective for all patients,as evidenced by the fact that only a minority of patients in these trials showed prolonged ***,there are several published phase III clinical trials that involve immune checkpoint inhibitors,peptide vaccines,dendritic cell vaccines,and ***,this review comprehensively overviews existing studies of targeted drugs and immunotherapy for glioma and discusses the challenge and perspective of targeted drugs and immunotherapy for glioma to clarify future directions.